Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the Phase II portion of this study is to assess the efficacy of
KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil,
leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in
patients with metastatic colorectal cancer.